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PURPOSE. To study longitudinal changes of anti-drug antibody (ADA) titers to recombinant
adeno-associated virus serotype 8 (rAAV8) capsid epitopes in nonhuman primates (NHP) and
patients.
METHODS. Three groups of six NHP each received subretinal injections (high dose: 1 3 1012
vector genomes [vg], low dose: 1 3 1011 vg, or vehicle only). Four additional animals
received intravitreal injections of the high dose (1 3 1012 vg). Three patients received 1 3
1010 vg as subretinal injections. ELISA quantified ADA levels at baseline and 1, 2, 3, 7, 28, and
90 days after surgery in NHP and at baseline and 1, 3, and 6 months after surgery in patients.
RESULTS. Two out of 22 animals lacked ADA titers at baseline and developed low ADA titers
toward the end of the study. Titers in the low-dose group stayed constant, while two of six
animals from the high-dose group developed titers that rose beyond the range of the assay. All
animals from the intravitreal control group showed a rise in ADA titer by day 7 that peaked at
day 28. Preliminary data from the clinical trial (NCT02610582) show no humoral immune
response in patients following subretinal delivery of 1 3 1010 vg.
CONCLUSIONS. No significant induction of ADA occurred in NHP when mimicking the clinical
scenario of subretinal delivery with a clinical-grade rAAV8 and concomitant immunosuppres-
sion. Likewise, clinical data showed no humoral immune response in patients. In contrast,
intravitreal delivery was associated with a substantial humoral immune response. Subretinal
delivery might be superior to an intravitreal application regarding immunologic aspects.
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Adeno-associated virus (AAV)-mediated gene therapies havebeen shown to be clinically safe and offer new possibilities
for the treatment of genetic diseases, such as blinding retinal
dystrophies. However, investigators have independently found
evidence of immune reactions against AAV vectors, the
transgene, or the transgene product.1–4 These include the full
range of active defense mechanisms including innate, humoral,
and cellular immunity. As such, clinical trials in hemophilia
patients have shown that circulating antibodies can effectively
inhibit transduction even at low titers, and that AAV-directed
CD8þ cells target and remove successfully transduced hepato-
cytes as virus-infected cells.5
In contrast to the treatment for hemophilia, where AAV
vectors are injected intravenously, relatively small doses are
administered in the immune-privileged space of the eye for
retinal disorders like Leber’s congenital amaurosis, choroidere-
mia, or achromatopsia. In 2008, different groups independently
reported a modest beneficial treatment effect of AAV2 for the
RPE65 mutation in LCA patients.6–8 In none of these trials were
major adverse advents reported in the following 5 years.
Clinically no inflammation unresponsive to steroids was
observed, and only two patients developed a transient antibody
reaction.9 One study reported a single case in which anti-capsid
antibodies emerged in a functional assay around day 14 but
declined later,6 and in another study some anti-capsid antibody
titers increased toward day 90 but were still low compared to
the overall mean.8 Amado et al.10 showed that subretinal
readministration of an AAV2 vector elicits a humoral immune
response against the viral capsid in large animals. However,
transduction was still possible under these conditions. This is in
line with the observation that readministration of subretinal
AAV (to the contralateral eye) in three adult patients did not
lead to a rise in antibody titer.11 Importantly, though,
intravitreal delivery of AAV2 has been shown to induce humoral
immune response in mice and block transduction in subse-
quent subretinal or intravitreal injections.12 Others have shown
that intravitreal delivery of AAV in NHP results in an increase of
anti-AAV antibodies and decreased transgene expression.13
Although a rise in antibody titer does not seem to be necessarily
harmful, safety of the patient is of paramount importance and
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the role of a potential humoral immune response should be
fully understood.
To further explore this we injected 22 NHP with different
doses of recombinant adeno-associated virus serotype 8
(rAAV8) as part of a formal toxicology and biodistribution
assessment toward regulatory approval of a phase I/II clinical
trial (NCT02610582). Subretinal or intravitreal administration
routes were used in a surgical setting identical to that in human
subjects (including perioperative steroids). We aimed to
elucidate whether a good manufacturing practice (GMP)-grade
AAV8 vector would lead to a humoral immune response in a
clinical scenario and whether route of delivery would make a
difference. Additionally, the same assay was used subsequently
to quantify anti-drug antibody (ADA) titers in human patients
following subretinal gene therapy (NCT02610582) with the
same vector.
METHODS
Animals and Study Design
A total of 22 NHP (Macaca fascicularis) were allocated into
four separate groups (Supplementary Table 1). Groups 1 to 3
consisted of six animals (three males/three females). Group 1
was treated with vehicle (balanced salt solution [BSS]; Alcon,
Freiburg im Breisgau, Germany) with 0.001% PF-68 (BASF,
Ludwigshafen am Rhein, Germany). Animals in groups 2 and 3
received the test item (rAAV8) in the left eye only via single
subretinal injection. Four animals (two males/two females)
were allocated to group 4 and received the same test item via
intravitreal injection. Animals in group 2 were treated with
low-dose (131011 vector genomes [vg]) and animals in groups
3 and 4 were treated with high dose (1 3 1012 vg). Animals
used in these studies were cared for and handled according to
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and after approval by the local authorities
(Regierungspraesidium) and in full compliance with the
guidelines of the European Community (EUVD 86/609/EEC)
for the care and use of laboratory animals, as well as in
accordance with good laboratory practice (GLP) standards as
defined by German GLP monitoring authorities and in
compliance with U.S. Food and Drug Administration GLP
regulations.
Vector and Vehicle
The AAV8 vector was produced according to GMP guidelines
by cotransfection of human embryonic kidney cells followed
by purification and concentration steps optimized for clinical
use of vector solution as reported previously.14
Surgery and Perisurgical Care of NHP
Animals received general isoflurane (Forane; Baxter GmbH,
Unterschleißheim, Germany) and local 2% oxybuprocain
(Conjuncain; Bausch&Lomb GmbH, Berlin, Germany) anesthe-
sia before preparing (peri-)orbital skin with 10% povidine
iodine solution and rinsing the conjunctival fornices with 1%
povidine iodine solution. Sterile surgical drapes and pediatric
lid specula were applied before a temporal canthotomy was
performed for improved access. Three 23-guage (G) trans-
conjunctival sclerotomies were made approximately 1.5 mm
posterior to the limbus and vitrectomy was performed as
completely as possible without affecting the lens. A localized
retinal detachment was induced through subretinal injection of
BSS (Alcon) using a 41-G cannula (DORC 1270.EXT; D.O.R.C.
Deutschland GmbH, Du¨sseldorf, Germany). Virus solution was
injected into the preformed bleb using a foot pedal–controlled
injection system (PentaSys II; Ruck GmbH, Eschweiler,
Germany). Before recovery, subconjunctival cefuroxime (125
mg; ratiopharm GmbH, Ulm, Germany) and dexamethasone (2
mg, ratiopharm GmbH) were administered to the operated eye.
Postoperative prophylactic treatment consisted of antibiotic
(0.5% Moxifloxacine; Pharm-Allergan GmbH, Frankfurt am
Main, Germany) and anti-inflammatory (1% Prednisolone;
Pharm-Allergan GmbH) eye drops given three times a day
each in the treated eye for 2 weeks and prednisone (Merck
Pharma GmbH, Darmstadt, Germany) 1 mg/kg intramuscularly
from day2 until day 5. In the course of the study all animals
received ophthalmoscopic screening (slit lamp, fundus biomi-
croscopy) for signs of inflammation at days 2, 3, 7, 22, 50, and
87.
Enzyme-Linked Immunosorbent Assay (ELISA)
Plasma samples were collected from each animal prior to
dosing and at days 1, 2, 3, 7, 28, and 90 post dosing. A total of
154 samples were analyzed using a sandwich ELISA strategy
utilizing a ELISA kit for the determination of AAV serotype 8
particles in cell culture supernatants or purified preparations
(PROGEN Biotechnik GmbH, Heidelberg, Germany; Art. No.:
PRAAV8). The microtiter strips, coated with a monoclonal
antibody specific for a conformational epitope on assembled
AAV8 capsids, were incubated with GMP-grade rAAV8. This
procedure completed the coating for the detection of the new
analyte: anti-AAV8 antibodies. Captured anti-AAV8 antibodies in
plasma samples were detected using an enzyme conjugate of a
rabbit anti-NHP antibody (rabbit anti human [and NHP] IgG
pAb Streptavidin Peroxidase Conjugate, Cat. No. 55221; MP
Biomedicals, Santa Ana, CA, USA). An anti-AAV8 biotin-
conjugated antibody, together with streptavidin peroxidase,
served as positive control. This antibody was used in a serial
dilution of 1:3 from 250 ng/mL down to 0.34 ng/mL. The
highest concentration of 250 ng/mL showed a hook effect and
was therefore regarded as out of the range of the assay. The
remaining seven standard dilutions covered the complete
range, returned from the plasma samples. Eight negative
controls were included on every ELISA plate. For the negative
controls, no plasma was added and the background was
calculated from the mean absorbance of these blanks. The
background mean was subtracted from the plasma samples.
After addition of substrate solution the color reaction was
measured photometrically at k ¼ 450 nm. In order to avoid
false-negative results due to very high concentrations of the
analyte, the plasma samples were measured in serial dilutions
(1:5, 1:25, 1:125).
To ensure the assay’s validity, coating controls, a dilution
sequence of positive controls, and a negative control with no
analyte were included on every ELISA plate. The optimal
assay setting was tested beforehand in a GLP confirming
proof of principle study. The following criteria were
implemented to ensure validity. Uncoated wells had to show
a low absorbance value (ODSTD0  0.2). Coating controls (13
109, 13 108, 13 107 vg/mL, no coating) had to show a dose
dependency in mean absorbance values. Coated wells
without analyte had to show a low absorbance value and
give a good signal-to-noise ratio when using a short time for
color reaction and using a blocking solution (ODno Plasma 
0.3). The mean absorbance value of the positive control wells
coated with 1 3 1010 vg/mL (standard 1, STD1) had to be ‡
1.0. The mean absorbance value of the positive controls
(standards 1–8) had to show a dose dependency (STD1 >
STD2 > STD3 > STD4 > STD5 > STD6 > STD7 > STD8).
Plasma from seroconverted animals had to show a clear dose–
dilution relationship.
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As these criteria were all met, the assay was considered to
be appropriate for the detection of anti-AAV8 antibodies.
Analysis
For the NHP samples, the titer was defined as the reciprocal
dilution of the plasma at which the linear, interpolated graph
for individual plasma intersects a so-called titer intercept line
(TIL). The range where the interpolated graph could intersect
the TIL was defined between 5 and 160. In this assay, the TIL
was defined as the 3.3-fold lower limit of quantification (LLOQ)
of the assay. Limit of detection (LOD) and LLOQ were
calculated according to German Institute for Standardization
(DIN) 32654, using the standard deviation (r(x0)) of negative
controls by the following approximation: LOD: 3 3 r(x0);
LLOQ: k3 33r(x0) (with k¼ 3 at relative confidence interval
[CIrel] ¼ 33%). In the case of clinical samples, absolute
absorbance values are reported of all dilutions tested and
compared in a longitudinal fashion.
Some samples did not yield quantifiable results. In these,
titers exceeded or stayed below the dilution range of 1:5 to
1:160. Because we calculated the titer using the slope between
different concentrations, in cases where the absorbance values
did not drop in line with the dilution series (see validation
criteria), the intersection with the TIL was outside the dilution
range (i.e., the reading did not meet the prespecified criteria of
validity). The most likely reason for this is the oversaturation of
the assay due to high titer concentrations or a technical error.
Likewise, plasma samples where all dilutions gave absorbance
values below the TIL were considered below the range.
Patients
Three patients (two male, one female) underwent the
procedure after written informed consent was given and
followed up according to the approved trial protocol
(NCT02610582). The vector was applied via subretinal
injection as described previously.14 All three patients received
1 3 1010 vg of the clinical-grade vector rAAV8.hCNGA3. To
monitor safety, clinical and ophthalmologic examinations were
performed at screening, directly after surgery, and 1, 2, 3 6 1,
14 6 3, 30 6 5, 90 6 7, and 180 6 7 days after surgery. Blood
samples were taken in all patients at screening, as well as 30 6
5, 90 6 7, and 180 6 7 days after surgery. The study was
carried out in accordance with the ethical principles of the
Declaration of Helsinki.
RESULTS
Nonhuman Primates (NHP)
For 141 of 154 NHP samples, a titer for rAAV-specific
antibodies could be calculated, while 13 samples (8%) were
out of the range of the assay. Of these, eight were above the
range of the assay (titer > 160), and five samples showed no
seroconversion (titer < 5). In total, 20 of 22 animals were
already seroconverted before application. The two seronega-
tive animals (28011M, 28017M), both allocated to the low-dose
group, developed very low antibody titers throughout the
observation period (maximum titer: 19, 28011M, day 28). No
sex-specific differences in the rAAV8 specific antibody titers
were observed.
In the vehicle control group (Fig. 1A), the change of titer
(day x  day 1) ranged from 28 in animal 28023M to þ50 in
animal 28062F. This represents the test variability and
individual titer fluctuations, which occur without an ongoing
inflammatory reaction since none of the animals received
vector. In the low-dose group (Fig. 1B) we observed titer
changes similar to the control group with a titer change range
from30 toþ36. As such, the antibody titers of the subretinal
low-dose group stayed constant over the entire observation
period. Although no statistical analysis is applicable, no titer
changes obviously different from those of the vehicle control
group were observed. Interindividual differences as well as the
time curve for the titers found in the low-dose group are similar
to those of the vehicle control group. In the high-dose group
(Fig. 1C), two animals had titers that were above the range of
the ELISA assay (animal 28060F day 28, animal 28063F day 7
and day 28). Where titers exceeded the range of the assay
(160), no titer change was calculated. With the three missing
values put aside, the titer change in group 3 ranged from 25
to þ68. The relevance of the missing values will be discussed
later. In the intravitreal control group (Fig. 1D), which received
the same dose as the high-dose group, the mean titer change
was most pronounced compared to all other groups. All
animals showed a tendency toward higher titers 7 to 28 days
after surgery. In three out of four animals, titers began to rise
by day 7, peaked at day 28, and declined toward day 90 but
remained elevated above baseline. The titer change on day 7
ranged fromþ34 toþ98 and on day 28 fromþ38 toþ140. The
maximum titer change was þ140 (animal 28057F day 28).
Individual titers for each animal and time point are shown in
Supplementary Figures S1 through S4.
Patient Samples
We tested plasma samples from the first three patients with
CNGA3-linked achromatopsia undergoing gene therapy
(NCT02610582), which applies the same vector construct
used in the NHP study above. The same ADA test was applied
and showed no humoral immune response within the first 6
months following subretinal delivery of 13 1010 vg (Fig. 2). All
three patients had quantifiable absorbance measurements at
baseline, which did not change significantly at 1, 3, or 6
months after subretinal vector delivery.
DISCUSSION
Through contact with wild-type AAV, humans develop anti-
bodies against the different serotypes in their first years of
life.15,16 Depending on the study, seroprevalence for AAV8
ranges from 15% to 30% of the population (AAV2: 30%–
60%)16,17 to 82% in Asian adult humans (AAV2: 97%).18
Seroprevalence for AAV8 in NHP is considered to be as high
as in humans or even higher.19 Accordingly, in our study, 20 of
22 animals were found to be seropositive for anti-rAAV8
antibodies, indicating a seroconversion before the first
treatment. Likewise, all patients from the first cohort (n ¼ 3)
of the clinical trial (NCT02610582) had quantifiable absor-
bance values in the ADA assay at baseline.
In general, after infection with a virus, the immune system
requires a few days to develop a specific humoral immune
response. Although it is difficult to exactly predict the
temporal dynamics of a humoral immune response against
AAV epitopes, antibody titers in a clinical gene therapy trial for
hemophilia using rAAV8 rose after 1 to 2 weeks.5 Antibody
titers rising in a similar time frame after rAAV8 delivery can
therefore be attributed to a specific humoral immune response.
This is what we observed in our intravitreal control group
where antibody titers began to climb on day 7 and peaked at
day 28 (no samples were taken in between, e.g., on day 14).
Hence, a specific humoral immune response in NHP after
intravitreal delivery of rAAV8 serves as a parsimonious
explanation.
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Although no evidence is at hand for the missing values of
the two animals of the high-dose group, 28060F and 28063F,
having the previous considerations in mind, one could
interpret these titers above the range of the assay on day 28
(28060F) and days 7 and 28 (28063F) as a humoral immune
response. In both animals, titers declined toward an elevated
level above baseline on day 90, which is consistent with what
we observed in the intravitreal control group. Apart from these
two animals, all other rAAV antibody titers in the high-dose
group, as well as all rAAV antibody titers of the low-dose group,
stayed constant over the 90-day observation period.
Since ELISA values for antibodies against AAV serotypes are
not comparable between different studies it is difficult to make
a decision on what titer change is considered a relevant
change—especially since high titers do not translate into
clinical findings. In our study we used the variability of control
group data to assess which change in titer was numerically
significant. It is important to remember, however, that this
does not equate to clinical significance. Indeed, we observed
no clinically relevant, test item–related changes in ophthalmo-
logic assessment throughout the in-life phase of the study.
Findings observed (limited and temporary anterior chamber
flare and cells, drusen, and pigment clumping) were either also
present before dose and thus regarded as background lesions
(e.g., drusen), or equally evident in groups 1 to 3 and therefore
related to the surgical procedure rather than the test item. The
fact that none of the 22 primates presented signs of a clinically
relevant inflammation shows that a rise in antibody titer cannot
be directly correlated to a clinically significant pathogenic
process. It may, however, become relevant in a scenario of
multiple injections and/or intravitreal applications.3,18 Intravit-
real may be considered the preferred route of administration
when targeting inner layers or wide areas of the retina.20
However, some authors have suggested that after intravitreal
injections, neutralizing antibodies are more likely to be
generated than after subretinal injections and that these
antibodies have the potential to inhibit effective gene
transfer.12,13 Part of the explanation for this enhanced humoral
immune response might be the fact that the shedding and
biodistribution of vector after intravitreal injections is consid-
erably higher.21
This study has certain limitations, including absence of
absolute thresholds of clinical relevance for levels of antibodies
against AAV8. Furthermore, there is no international standard
FIGURE 1. Individual titer change in individual animals presented as D to baseline (day 1). (A) Control group, (B) low-dose group (13 1011 vg), (C)
high-dose group (13 1012), (D) intravitreal high-dose group (13 1012). Titers are calculated as described in Methods. Where titers exceeded the
range of the assay (upper range of titer calculation: 1:160), no titer and no titer change could be calculated ([C] 28060F day 7 and 28063F days 7 and
28; [A] 28010M at all time points and therefore not included in graph).
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for benchmarking across studies. As such, dilution series and
longitudinal follow-up are important aspects in these investi-
gations. Another limitation is the lack of true technical repeats
in the ELISA. Instead, each sample was measured in a dilution
sequence and the titer calculated by using the slope instead of
single values. This has the added benefit of accounting for
differences in antibody affinity as a function of epitope
concentration.
One needs to be cautious when extrapolating results
from studies in NHP to the clinical situation because the
response of the immune system of NHP to the therapeutic
vector may differ from that of human subjects. However, we
believe that our findings may help guide study designs of
future clinical gene therapy trials. We argue that this assay
can specifically detect antibodies against AAV8 epitopes and
is appropriate for the comparison of pre- and postdose
plasma specimens. Since our results rely on rAAV8, we can
only speculate about the effects of other serotypes. It seems
possible, though, that the time course of the humoral
immune response as well as the effects of different routes of
administration may be similar for the commonly used vector
AAV2 and other serotypes.
In conclusion, our results show an excellent safety profile,
especially regarding the low dose (1 3 1011 vg). This is
important, as this dose was chosen as the highest dose used
for the c l in ical t r i a l in achromatops ia pat ients
(NCT02610582). Groups 3 and 4, having received 1 3 1012
vg, showed more equivocal results, with some samples
exceeding the range of the ADA assay. In general, the route
of administration seems to have dictated the humoral immune
response against AAV8: While an intravitreal approach
promises the potential of panretinal transduction without
the challenges of subretinal surgery, this study adds evidence
to the observation that intravitreal injections are associated
with a higher risk for humoral immune responses compared
to subretinal delivery of AAV vectors. An ongoing trial with
intravitreal application of AAV8 for X-linked juvenile retinos-
chisis (NCT02416622) will help to further clarify this
observation.
More research is needed to understand the complex
reaction to AAV in the immune-privileged eye. The ocular
immune response against AAV beginning with innate mecha-
nisms and leading to specific humoral/cellular immunity is still
poorly understood. It is of eminent importance to gain a good
knowledge of the mechanisms underlying the antiviral defense
mechanisms of the visual system. This will allow further
improvement of safety and enhancement of efficacy of AAV-
mediated gene therapies in the eye.
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